The Role of the Extracellular Matrix in Primary Myelofibrosis

Overview

Journal Blood Cancer J

Date 2017 Feb 4

PMID 28157219

Citations 31

Authors

O Leiva

S K Ng

S Chitalia

A Balduini

S Matsuura

K Ravid

Affiliations

Soon will be listed here.

Abstract

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that arises from clonal proliferation of hematopoietic stem cells and leads to progressive bone marrow (BM) fibrosis. While cellular mutations involved in the development of PMF have been heavily investigated, noteworthy is the important role the extracellular matrix (ECM) plays in the progression of BM fibrosis. This review surveys ECM proteins contributors of PMF, and highlights how better understanding of the control of the ECM within the BM niche may lead to combined therapeutic options in PMF.

Citing Articles

Investigational drugs in early phase trials for myelofibrosis.

Arora S, Vachhani P, Bose P Expert Opin Investig Drugs. 2024; 33(12):1231-1244.

PMID: 39604120 PMC: 11669310. DOI: 10.1080/13543784.2024.2434696.

Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications-A Narrative Review.

Todor S, Ichim C, Boicean A, Mihaila R Curr Issues Mol Biol. 2024; 46(8):8407-8423.

PMID: 39194713 PMC: 11353264. DOI: 10.3390/cimb46080496.

Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis.

Abbonante V, Karkempetzaki A, Leon C, Krishnan A, Huang N, Di Buduo C Am J Hematol. 2024; 99(3):336-349.

PMID: 38165047 PMC: 10922533. DOI: 10.1002/ajh.27184.

Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms.

Pritchard J, Pearce J, Snoeren I, Fuchs S, Gotz K, Peisker F Cell Rep. 2023; 43(1):113608.

PMID: 38117649 PMC: 10828549. DOI: 10.1016/j.celrep.2023.113608.

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.

Hasselbalch H, Junker P, Skov V, Kjaer L, Knudsen T, Larsen M Cancers (Basel). 2023; 15(17).

PMID: 37686599 PMC: 10486581. DOI: 10.3390/cancers15174323.

References

Goldenson B, Kirsammer G, Stankiewicz M, Wen Q, Crispino J . Aurora kinase A is required for hematopoiesis but is dispensable for murine megakaryocyte endomitosis and differentiation. Blood. 2015; 125(13):2141-50. PMC: 4375110. DOI: 10.1182/blood-2014-12-615401. View

Guerrouahen B, Al-Hijji I, Rafii Tabrizi A . Osteoblastic and vascular endothelial niches, their control on normal hematopoietic stem cells, and their consequences on the development of leukemia. Stem Cells Int. 2011; 2011:375857. PMC: 3236318. DOI: 10.4061/2011/375857. View

Stein B, Cervantes F, Giles F, Harrison C, Verstovsek S . Novel therapies for myelofibrosis. Leuk Lymphoma. 2015; 56(10):2768-78. PMC: 5008691. DOI: 10.3109/10428194.2015.1037762. View

Sirhan S, Lasho T, Hanson C, Mesa R, Pardanani A, Tefferi A . The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol. 2008; 83(5):363-5. DOI: 10.1002/ajh.21149. View

Lin T, Matsui W . Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targets Ther. 2012; 5:47-58. PMC: 3325001. DOI: 10.2147/OTT.S21957. View

Le Bousse-Kerdiles M, Chevillard S, Charpentier A, Romquin N, Clay D, Smadja-Joffe F . Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood. 1996; 88(12):4534-46. View

Watson S . Platelet activation by extracellular matrix proteins in haemostasis and thrombosis. Curr Pharm Des. 2009; 15(12):1358-72. DOI: 10.2174/138161209787846702. View

Rosti V, Villani L, Riboni R, Poletto V, Bonetti E, Tozzi L . Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood. 2012; 121(2):360-8. DOI: 10.1182/blood-2012-01-404889. View

Wilson A, Trumpp A . Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006; 6(2):93-106. DOI: 10.1038/nri1779. View

10.

Calvi L, Adams G, Weibrecht K, Weber J, Olson D, Knight M . Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425(6960):841-6. DOI: 10.1038/nature02040. View

11.

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

12.

Passamonti F, Maffioli M, Cervantes F, Vannucchi A, Morra E, Barbui T . Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014; 123(12):1833-5. DOI: 10.1182/blood-2013-12-544411. View

13.

Tefferi A, Guglielmelli P, Larson D, Finke C, Wassie E, Pieri L . Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014; 124(16):2507-13. PMC: 4199952. DOI: 10.1182/blood-2014-05-579136. View

14.

Lin C, Kaushansky K, Zhan H . JAK2-mutant vascular niche contributes to JAK2 clonal expansion in myeloproliferative neoplasms. Blood Cells Mol Dis. 2016; 62:42-48. PMC: 5135612. DOI: 10.1016/j.bcmd.2016.09.004. View

15.

Christiansen A, Detmar M . Lymphangiogenesis and cancer. Genes Cancer. 2012; 2(12):1146-58. PMC: 3411123. DOI: 10.1177/1947601911423028. View

16.

Schliemann C, Gerss J, Wiebe S, Mikesch J, Knoblauch N, Sauer T . A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia. PLoS One. 2016; 11(10):e0164499. PMC: 5055288. DOI: 10.1371/journal.pone.0164499. View

17.

Martyre M, Magdelenat H, Calvo F . Interferon-gamma in vivo reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1991; 77(3):431-5. DOI: 10.1111/j.1365-2141.1991.tb08596.x. View

18.

Tefferi A, Vardiman J . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2007; 22(1):14-22. DOI: 10.1038/sj.leu.2404955. View

19.

Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

20.

Schneider R, Ziegler S, Leisten I, Ferreira M, Schumacher A, Rath B . Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms. J Hematol Oncol. 2014; 7:92. PMC: 4271470. DOI: 10.1186/s13045-014-0092-2. View